Eyenovia (NASDAQ:EYEN) Announces Earnings Results

Eyenovia (NASDAQ:EYEN) issued its quarterly earnings data on Tuesday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02, Zacks reports. Eyenovia had a negative net margin of 116,506.25% and a negative return on equity of 547.46%. During the same quarter last year, the business earned ($0.18) EPS.

Eyenovia Price Performance

Shares of EYEN traded down $0.10 during trading hours on Wednesday, reaching $0.40. The stock had a trading volume of 2,414,594 shares, compared to its average volume of 1,198,235. The stock has a market capitalization of $25.75 million, a PE ratio of -0.52 and a beta of 1.75. The company has a debt-to-equity ratio of 3.72, a quick ratio of 0.27 and a current ratio of 0.46. The company’s 50-day moving average is $0.51 and its two-hundred day moving average is $0.72. Eyenovia has a 12 month low of $0.37 and a 12 month high of $2.57.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. William Blair upgraded shares of Eyenovia to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research note on Wednesday.

Insider Activity at Eyenovia

In related news, CEO Michael M. Rowe bought 50,000 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was acquired at an average cost of $0.57 per share, with a total value of $28,500.00. Following the transaction, the chief executive officer now directly owns 82,927 shares in the company, valued at approximately $47,268.39. This trade represents a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.10% of the stock is owned by company insiders.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.